Your session is about to expire
← Back to Search
Cabozantinib + Pembrolizumab for Lung Cancer (LUNG-IST-127 Trial)
LUNG-IST-127 Trial Summary
This trial assesses combo therapy of cabozantinib and pembrolizumab to treat metastatic squamous NSCLC after induction with pembrolizumab, carboplatin and nab/paclitaxel. It looks at efficacy, safety and quality of life.
LUNG-IST-127 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.LUNG-IST-127 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My recent tests show my organs are functioning well.I haven't had radiation for bone metastasis in the last 2 weeks or any radiation in the last 4 weeks.I haven't taken any kinase inhibitor medication in the last 2 weeks.I haven't had any cancer treatment in the last 4 weeks.I have been treated with cabozantinib before.My cancer has spread to or is surrounding major blood vessels.My cancer has a specific genetic change that can be treated with approved drugs.I have recovered from previous treatment side effects, or they are minor and stable.I am mentally and physically capable of participating in a clinical trial.My lung cancer is confirmed to be squamous non-small cell type.I will use birth control during and for 4 months after my treatment ends.I have stage IV non-small cell lung cancer and haven't been treated for it yet.My tumor has been tested for PD-L1.I am not pregnant, and if I can have children, I've had a negative pregnancy test recently.I am currently on medication for an infection.I am 18 years old or older.I have lung issues seen on scans, or known airway disease, and no new or worsening cavities in my lungs if on maintenance therapy.I understand and agree to follow the study's requirements.I have been active and mostly self-sufficient in the last 28 days.I do not have any severe illnesses that would make it unsafe for me to join the study.My cancer did not worsen after initial treatment.
- Group 1: Single
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA granted clearance to Single?
"Our team at Power rated the safety of Single a 2, as it is currently undergoing Phase 2 trials. This suggests that while there are preliminary data indicating its security, no evidence exists to confirm efficacy."
Is participant recruitment for this trial currently underway?
"According to the information on clinicaltrials.gov, this research project is presently seeking participants; it was first uploaded on December 1st 2022 and has been updated most recently on December 12th 2022."
How many individuals are currently taking part in this clinical experiment?
"Affirmative, the details available on clinicaltrials.gov indicate that this trial is actively looking for participants. It was initially posted on December 1st 2022 and its information has been revised as recently as December 12th 2022. The study intends to enrol 325 patients from one location."
Share this study with friends
Copy Link
Messenger